

PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY (Chapter I of the Patent Cooperation Treaty)

(PCT Rule 44bis)

Applicant's or agent's file reference BIOZ' P29774PC	FOR FURTHER ACTION		See item 4 below
International application No. PCT/GB2004/002996	International filing date (<i>day/month/year</i>) 09 July 2004 (09.07.2004)	Priority date (<i>day/month/year</i>) 09 July 2003 (09.07.2003)	
International Patent Classification (8th edition unless older edition indicated) See relevant information in Form PCT/ISA/237			
Applicant BIOLIPOX AB			

1. This international preliminary report on patentability (Chapter I) is issued by the International Bureau on behalf of the International Searching Authority under Rule 44 *bis*.1(a).

2. This REPORT consists of a total of 5 sheets, including this cover sheet.

In the attached sheets, any reference to the written opinion of the International Searching Authority should be read as a reference to the international preliminary report on patentability (Chapter I) instead.

3. This report contains indications relating to the following items:

- | | |
|--|---|
| <input checked="" type="checkbox"/> Box No. I | Basis of the report |
| <input checked="" type="checkbox"/> Box No. II | Priority |
| <input type="checkbox"/> Box No. III | Non-establishment of opinion with regard to novelty, inventive step and industrial applicability |
| <input type="checkbox"/> Box No. IV | Lack of unity of invention |
| <input checked="" type="checkbox"/> Box No. V | Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement |
| <input type="checkbox"/> Box No. VI | Certain documents cited |
| <input type="checkbox"/> Box No. VII | Certain defects in the international application |
| <input type="checkbox"/> Box No. VIII | Certain observations on the international application |

4. The International Bureau will communicate this report to designated Offices in accordance with Rules 44bis.3(c) and 93bis.1 but not, except where the applicant makes an express request under Article 23(2), before the expiration of 30 months from the priority date (Rule 44bis .2).

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland Facsimile No. +41 22 740 14 35	Date of issuance of this report 09 January 2006 (09.01.2006)
	Authorized officer Nora Lindner Telephone No. +41 22 338 89 65

Form PCT/IB/373 (January 2004)

BEST AVAILABLE COPY

PATENT COOPERATION TREATY

From the
INTERNATIONAL SEARCHING AUTHORITY

REC'D 14 OCT 2004

WIPO

PCT

PCT

To:

see form PCT/ISA/220

WRITTEN OPINION OF THE
INTERNATIONAL SEARCHING AUTHORITY
(PCT Rule 43bis.1)

Date of mailing

(day/month/year) see form PCT/ISA/210 (second sheet)

Applicant's or agent's file reference
see form PCT/ISA/220

FOR FURTHER ACTION
See paragraph 2 below

International application No.
PCT/GB2004/002996

International filing date (day/month/year)
09.07.2004

Priority date (day/month/year)
09.07.2003

International Patent Classification (IPC) or both national classification and IPC
C07D403/04, C07D409/04, A61K31/404, A61P29/00

Applicant
BIOLIPOX AB

1. This opinion contains indications relating to the following items:

- ☒ Box No. I Basis of the opinion
- ☒ Box No. II Priority
- ☐ Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- ☐ Box No. IV Lack of unity of invention
- ☒ Box No. V Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- ☐ Box No. VI Certain documents cited
- ☐ Box No. VII Certain defects in the international application
- ☐ Box No. VIII Certain observations on the international application

2. FURTHER ACTION

If a demand for international preliminary examination is made, this opinion will usually be considered to be a written opinion of the International Preliminary Examining Authority ("IPEA"). However, this does not apply where the applicant chooses an Authority other than this one to be the IPEA and the chosen IPEA has notified the International Bureau under Rule 66.1bis(b) that written opinions of this International Searching Authority will not be so considered.

If this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the IPEA a written reply together, where appropriate, with amendments, before the expiration of three months from the date of mailing of Form PCT/ISA/220 or before the expiration of 22 months from the priority date, whichever expires later.

For further options, see Form PCT/ISA/220.

3. For further details, see notes to Form PCT/ISA/220.

Name and mailing address of the ISA:



European Patent Office
D-80298 Munich
Tel. +49 89 2399 - 0 Tx: 523656 epmu d
Fax: +49 89 2399 - 4465

Authorized Officer

Menegaki, F

Telephone No. +49 89 2399-8277



WRITTEN OPINION OF THE
INTERNATIONAL SEARCHING AUTHORITY

International application No.
PCT/GB2004/002996

Box No. I Basis of the opinion

1. With regard to the **language**, this opinion has been established on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.
 - ☐ This opinion has been established on the basis of a translation from the original language into the following language, which is the language of a translation furnished for the purposes of international search (under Rules 12.3 and 23.1(b)).
2. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application and necessary to the claimed invention, this opinion has been established on the basis of:
 - a. type of material:
 - ☐ a sequence listing
 - ☐ table(s) related to the sequence listing
 - b. format of material:
 - ☐ in written format
 - ☐ in computer readable form
 - c. time of filing/furnishing:
 - ☐ contained in the international application as filed.
 - ☐ filed together with the international application in computer readable form.
 - ☐ furnished subsequently to this Authority for the purposes of search.
3. ☐ In addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
4. Additional comments:

BEST AVAILABLE COPY

WRITTEN OPINION OF THE
INTERNATIONAL SEARCHING AUTHORITY

International application No.
PCT/GB2004/002996

Box No. II Priority

1. ☒ The following document has not been furnished:

☒ copy of the earlier application whose priority has been claimed (Rule 43*bis*.1 and 66.7(a)).

☐ translation of the earlier application whose priority has been claimed (Rule 43*bis*.1 and 66.7(b)).

Consequently it has not been possible to consider the validity of the priority claim. This opinion has nevertheless been established on the assumption that the relevant date is the claimed priority date.

2. ☐ This opinion has been established as if no priority had been claimed due to the fact that the priority claim has been found invalid (Rules 43*bis*.1 and 64.1). Thus for the purposes of this opinion, the international filing date indicated above is considered to be the relevant date.

3. Additional observations, if necessary:

Box No. V Reasoned statement under Rule 43*bis*.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Yes: Claims	1-39
	No: Claims	
Inventive step (IS)	Yes: Claims	1-39
	No: Claims	
Industrial applicability (IA)	Yes: Claims	1-39
	No: Claims	

2. Citations and explanations

see separate sheet

BEST AVAILABLE COPY

Re Item V.

1 The following documents are referred to in this communication:

D1 : EP 0 985 666 A (PFIZER) 15 March 2000 (2000-03-15)

D2 : WO 99/05104 A (PFIZER PHARMA ; FUJIWARA SHINYA (JP); NAKAO
KAZUNARI (JP); UCHIDA CHIK) 4 February 1999 (1999-02-04)

D3 : WO 00/46198 A (FAULL ALAN WELLINGTON ; KETTLE JASON (GB);
ASTRAZENECA US LIMITED (GB)) 10 August 2000 (2000-08-10)

The above documents differ from the present subject-matter mainly due to the (hetero-)aryl substituent R^{2-5} and therefore, the requirements of Art.33(2) EPC appear to be fulfilled.

With regard to inventive step the problem underlying the invention appears to be the provision of novel antiinflammatory indole derivatives of formula (I), in particular mPGES-1inhibitors which reduce formation of arachidonic acid metabolite PGE2. Documents (D1)/(D2) disclose COX-2 inhibitors differing due to present R^{2-5} as well as the substituent in 1-position of the indole moiety and are not considered to be relevant. Document (D3) discloses indole derivatives acting as antiinflammatory agents due to MCP-1 inhibiting activity, which bear no (hetero-)aryl substituent compared with present R^{2-5} definition.

It is considered that the skilled man faced with the problem to provide novel antiinflammatory indole derivatives would not have expected that the introduction of a (hetero-)aryl substituent R^{2-5} would lead to compounds having antiinflammatory, in particular mPGES-1 inhibiting properties. Therefore, the requirements of Art.33(3) EPC appear to be fulfilled, provided that all claimed compounds possess the specific activity. In this connection reference is made to the broad definition of the essential group R^{2-5} "(hetero-)aryl", without further specifying the number of C-atoms or heteroatoms; the definition Z=spacer group. The substantiation of the claimed activity is based on the general data on p.48-50, which have been no further specified by the Applicant.

BEST AVAILABLE COPY